Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : NELL1
Therapeutic Area : Musculoskeletal
Study Phase : Preclinical
Sponsor : WallachBeth Capital
Deal Size : $5.1 million
Deal Type : Public Offering
Bone Biologics Announces Closing of $5,100,000 Underwritten Public Offering
Details : The Company plans to use the net proceeds to fund its planned clinical trials for NELL-1, maintain and extend its patent portfolio, retain contract research organizations, and for working capital and other general corporate purposes.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Undisclosed
December 10, 2022
Lead Product(s) : NELL1
Therapeutic Area : Musculoskeletal
Highest Development Status : Preclinical
Sponsor : WallachBeth Capital
Deal Size : $5.1 million
Deal Type : Public Offering
Lead Product(s) : rhNELL-1
Therapeutic Area : Musculoskeletal
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Bone Biologics Preclinical Study Shows rhNELL-1 Effectively Promotes Bone Formation
Details : Bone Biologics has completed a preclinical study, which shows its rhNELL-1 growth factor effectively promotes bone formation in a phylogenetically advanced spine model.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
August 01, 2020
Lead Product(s) : rhNELL-1
Therapeutic Area : Musculoskeletal
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable